Polymorphism of μ-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response

Anesthesiology

Volumn 102, Issue 3, 2005, Pages 522-530

  Romberg, Raymonda R ^a   Olofsen, Erik ^a   Bijl, Hans ^a   Taschner, Peter E M ^b   Teppema, Luc J ^a   Sarton, Elise Y ^a   Van Kleef, Jack W ^a   Dahan, Albert ^a,b  

^a Department of Anesthesiology ^*

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR; OPIATE;

ADULT; ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANALGESIA; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; GENE; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; OPRM1 GENE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR GENE; RESPIRATION DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ANALGESIA; ANALGESICS, OPIOID; FEMALE; HUMANS; MALE; MORPHINE DERIVATIVES; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; RESPIRATION;

EID: 14644441712     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200503000-00008     Document Type: Conference Paper

References (29)

1. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, LeMeur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996; 383:819-23
2. Dahan A, Sarton E, Teppema L, Olievier C, Nieuwenhuijs D, Matthes HWD, Kieffer BL: Anesthetic potency and influence of morphine and sevoflurane on respiration in ì-opioid receptor knockout mice. ANESTHESIOLOGY 2001; 94:824-32
3. Romberg R, Sarton E, Teppema L, Matthes MWD, Kieffer BL, Dahan A: Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and μ-opioid receptor deficient mice. Br J Anaesth 2003; 91:862-70
4. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95:9608-13
5. Beyer A, Koch T, Schröder H, Schulz S, Hölt V: Effect of A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004; 89:553-60
6. 118G polymorphism and substance dependence. Am J Med Gen 2001; 105:114-9
7. Comptom P, Geschwind DH, Alarcón M: Association between human μ-opioid receptor gene polymorphism, pain tolerance and opioid addiction. Am J Med Gen B 2003; 121B:76-82
8. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A: The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26: 106-14
9. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR: Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the μ-opioid receptor locus (Oprm1). Am J Med Gen B 2003; 118B:60-5
10. Miller GM, Bendor J, Tiefenbacher S, Yang H, Novak MA, Madras BK: A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: Association with stress response and aggression. Mol Psychiatry 2004; 9:99-108
11. Lotsen J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger: The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12:3-9
12. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen P: The 118A>G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48:1232-39
13. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73:107-21
14. Romberg R, Olofsen E, Sarton E, denHartigh J, Taschner PEM, Dahan A: Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide induced analgesia in healthy volunteers. ANESTHESIOLOGY 2004; 100:120-33
15. Landau R, Cahana A, Smiley RM, Antonarakis SE, Blouin JL: Genetic variability of μ-opioid receptor in an obstetric population. ANESTHESIOLOGY 2004; 100:1030-3
16. Lötsch J, Zimmerman M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G: Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide? ANESTHESIOLOGY 2002; 97:814-9
17. Hirota T, Ieiri I, Takane H, Sano H, Kawamato K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizo E, Higuchi S, Otsubo K: Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Disp 2003; 31:677-80
18. Dahan A, deGoede J, Berkenbosch A, Olievier ICW: The influence of oxygen on the ventilatory response to carbon dioxide in man. J Physiol (Lond) 1990; 428:485-99
19. Beal SL, Sheiner LB: NONMEM User's Guide. San Francisco, University of California, San Francisco, 1999
20. Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D, Burm A, Teppema L, Dahan A: Sex differences in morphine analgesia. ANESTHESIOLOGY 2000; 93:1245-54
21. Dahan A, Nieuwenhuijs D, Olofsen E, Sarton E, Romberg R, Teppema L: Response surface modeling of alfentanil-sevoflurane interaction on cardiorespiratory control and Bispectral Index. ANESTHESIOLOGY 2001; 94: 982-91
22. Wang D, Quiallan JM, Winans K, Lucas JL, Sadée W: Single nucleotide polymorphisms in the human μ opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 2001; 276:34624-30
23. Rossi GC, Leventhal I, Pan YX, Cole J, Su W, Bodnar RJ, Pasternak GW: Antisense mapping of MOR-1 in rats: Distinguishing between morphine and morphine-60-glucuronide antinociception. J Pharmacol Exp Ther 1997; 281: 109-14
24. Schuller AGP, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, Unterwald EM, Pasternak GW, Pintar JE: Retention of heroin and morphine-6β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 1999; 2:151-6
25. Lötsch J, Zimmerman M, Darimont J, Dudziak R, Skarke C, Geisslinger G: Does the A118G polymorphism at the μ opioid receptor gene protect against morphine-6-glucuronide toxicity? ANESTHESIOLOGY 2002; 97:814-9
26. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A: The pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ANESTHESIOLOGY 2003; 99:788-98
27. Huwyler J, Drewe J, Kuseman C, Fricker G: Evidence for P-glycoprotein-modulated penetration of morphine-6glucuronide into brain capillary endothelium. Br J Pharmacol 1996; 118:1879-85
28. Dahan A, Romberg R, Teppema L, Sarton E, Bijl H, Olofsen E: Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. ANESTHESIOLOGY 2004; 101:1201-9
29. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A: Increased margin of safety of morphine-6-glucuronide relative to morphine (letter). ANESTHESIOLOGY 2004; 100:1622